Catalog Number: 1038
Alternate Names: (R)-(+)-WIN 55212
Chemical Name: (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate
Biological Activity
Nanomolar affinity cannabinoid receptor agonist (Ki values are 62.3 and 3.3 nM at the human cloned CB1 and CB2 receptors respectively). S-enantiomer WIN 55,212-3 mesylate (Cat. No. 2327) also available.
Technical Data
  • M.Wt:
  • Formula:
  • Solubility:
    Soluble to 30 mM in ethanol with gentle warming and to 100 mM in DMSO with gentle warming
  • Purity:
  • Storage:
    Store at +4°C
  • CAS No:
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis. All Tocris products are intended for laboratory research use only.
Additional Information
Other Product-Specific Information:

The citations listed below are publications that use Tocris products. Selected citations for WIN 55,212-2 mesylate include:

Showing Results 1 - 10 of 58

  1. Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia
    Authors: Szücs Et al.
    Neuroscience Letters
  2. Correlations between the Memory-Related Behavior and the Level of Oxidative Stress Biomarkers in the Mice Brain, Provoked by an Acute Administration of CB Receptor Ligands.
    Authors: Kruk-Slomka Et al.
    Neural Plast
  3. Cannabinoid WIN-55,212-2 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1.
    Authors: Kong Et al.
    Int J Neuropsychopharmacol
  4. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.
    Authors: Mahmoud Et al.
    Mol Pharmacol
  5. TRPA1 mediates the hypothermic action of acetaminophen.
    Authors: Gentry Et al.
    Br J Pharmacol
  6. Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2.
    Authors: Fanarioti Et al.
    Int J Mol Sci
  7. Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals.
    Authors: Lin Et al.
    Sci Rep
  8. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
    Authors: Hruba and McMahon
  9. Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1.
    Authors: Flores-Otero Et al.
    Nat Commun
  10. Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.
    Authors: Levin Et al.
    Eur J Pharmacol
  11. Miswiring the brain: △9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway.
    Authors: Tortoriello Et al.
    Br J Pharmacol
  12. The calcium-sensitive σ-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases.
    Authors: Sánchez-Blázquez Et al.
    Mol Med Rep
  13. Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis.
    Authors: Li Et al.
    Lab Invest
  14. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
    Authors: Baillie Et al.
    Mol Pharmacol
  15. Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats.
    Authors: Caiati and Cherubini
    Front Cell Neurosci
  16. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
    Authors: Prather Et al.
    Biochem Biophys Res Commun
  17. Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.
    Authors: Abush and Akirav
  18. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.
    Authors: Marcu Et al.
    J Pharmacol Exp Ther
  19. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
    Authors: Marini Et al.
    Br J Pharmacol
  20. The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells.
    Authors: Sreevalsan and Safe
    Mol Cancer Ther
  21. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
    Authors: Brents Et al.
    Biochem Pharmacol
  22. CB1 receptor autoradiographic characterization of the individual differences in approach and avoidance motivation.
    Authors: Laricchiuta Et al.
    PLoS One
  23. Developmental regulation of CB1-mediated spike-time dependent depression at immature mossy fiber-CA3 synapses.
    Authors: Caiati Et al.
    Sci Rep
  24. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.
    Authors: Liu Et al.
    Mol Cancer Ther
  25. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
    Authors: Brents Et al.
    PLoS One
  26. Cannabinoids attenuate hippocampal γ oscillations by suppressing excitatory synaptic input onto CA3 pyramidal neurons and fast spiking basket cells.
    Authors: Holderith Et al.
    J Neurosci
  27. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.
    Authors: Preet Et al.
    Cancer Prev Res (Phila)
  28. Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice.
    Authors: Pan Et al.
    J Cell Biol
  29. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.
    Authors: Schicho Et al.
    Inflamm Bowel Dis
  30. The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages.
    Authors: Hao Et al.
    J Neurosci
  31. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
    Authors: Jones Et al.
    Br J Pharmacol
  32. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy.
    Authors: Wyeth Et al.
    J Neurosci
  33. Cannabinoids excite circadian clock neurons.
    Authors: Acuna-Goycolea Et al.
    PLoS One
  34. Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons.
    Authors: Farkas Et al.
    J Biomol Screen
  35. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses.
    Authors: Kim and Alger
    Nat Neurosci
  36. Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.
    Authors: Garzón Et al.
    Mol Pain
  37. Cannabinoid regulation of nitric oxide synthase I (nNOS) in neuronal cells.
    Authors: Carney Et al.
    J Neuroimmune Pharmacol
  38. Effects of cannabinoids on caffeine contractures in slow and fast skeletal muscle fibers of the frog.
    Authors: Huerta Et al.
    J Membr Biol
  39. Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.
    Authors: Ho and Gardiner
    Front Pharmacol
  40. Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter β-arrestin assay.
    Authors: McGuinness Et al.
    Int J Neuropsychopharmacol
  41. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons.
    Authors: Gibson Et al.
  42. Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others.
    Authors: Karson Et al.
    J Physiol
  43. Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
    Authors: Kapur Et al.
    J Pharmacol Exp Ther
  44. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.
    Authors: Potenzieri Et al.
    Brain Res
  45. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
    Authors: Marinelli Et al.
  46. Calcium release from presynaptic internal stores is required for ethanol to increase spontaneous γ-aminobutyric acid release onto cerebellum Purkinje neurons.
    Authors: Kelm Et al.
    J Neurosci
  47. Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum.
    Authors: Narushima Et al.
    J Neurosci
  48. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal.
    Authors: Huang Et al.
    J Neurosci
  49. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Authors: Pertwee Et al.
    Br J Pharmacol
  50. Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus.
    Authors: Hoffman Et al.
    J Lipid Res
  51. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Authors: Thomas Et al.
    Br J Pharmacol
  52. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves.
    Authors: MacNaughton Et al.
    Eur J Neurosci
  53. Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors.
    Authors: Galarreta Et al.
    J Pharmacol Exp Ther
  54. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.
    Authors: Costa Et al.
    J Neurosci
  55. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response.
    Authors: Williams Et al.
    EMBO J
  56. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus.
    Authors: Craib Et al.
    PLoS One
  57. Feeding induced by cannabinoids is mediated independently of the melanocortin system.
    Authors: Sinnayah Et al.
  58. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells.
    Authors: Michalski Et al.
    Am J Physiol Gastrointest Liver Physiol
Expand to show all
Tocris Small Molecules
Description Application Cat# Citations Images  

WIN 55,212-3 mesylate

2327 1  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....
Tocris Bioscience is the leading supplier of novel and exclusive tools for life science research with over 30 years' experience in the industry. Tocris is a Bio-Techne brand.

Order Details


Contact Information

Molarity Calculator
Calculate the mass, volume or concentration required for a solution

The molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) x Volume (L) x Molecular Weight (g/mol)
An example of a molarity calculation using the molarity calculator:
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?

R&D Systems Guarantee

or select another batch:


Customer Information